Overall Survival Results of KEYNOTE-564

from Medical Digest & Congress Report · host Medical Congress News

We asked Professor Stefan N. Symeonides, one of the authors of the KEYNOTE-564 study, about the trial and the new data presented on overall survival at ASCO GU 2024. Adjuvant treatment with pembrolizumab has significantly improved overall survival in patients with clear cell renal cell carcinoma who are at high risk of recurrence after surgery, according to an updated analysis of the KEYNOTE-564 trial. Video: https://medicaldigest.org/scientific-contents/standalonecontent:overall-survival-results-keynote-564

Episode metadata supplied by the publisher feed · Published Apr 5, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

Overall Survival Results of KEYNOTE-564

0:00 13:29

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Medical Digest & Congress Report?

This episode is 13 minutes long.

When was this Medical Digest & Congress Report episode published?

This episode was published on April 5, 2024.

Can I download this Medical Digest & Congress Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!